Podcast by Taylor & Francis Group
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
43%
Guest openness
Selective
Sign up to generate a grounded pitch for Taylor & Francis.
Signup to Generate a PitchRecent episodes include "Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer" (30 October 2026, 14 minutes), "The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer" (29 October 2026, 15 minutes), and "Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study" (28 October 2026, 16 minutes).
Taylor & Francis publishes roughly daily, with episodes averaging 17 minutes across 325 episodes.
Booking probability for Taylor & Francis is 43%, and the host is rated Selective on guests. Taylor & Francis requires a Pod Score of 80 or higher. Taylor & Francis's contact route on record: public web form.
The strongest fits for Taylor & Francis are Scientific Research & Development. Taylor & Francis has a science audience.
Taylor & Francis is a science podcast with 325 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Taylor & Francis
Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer by Taylor & Francis Group
Taylor & Francis
In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included...
Taylor & Francis
Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the...
Taylor & Francis
Patients with advanced breast cancer in which the cancer cells have the receptor for the hormone estrogen and/or progesterone are typically treated with an aromatase inhibitor, a hormone therapy that decreases estrogen...
Taylor & Francis
The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the...
Taylor & Francis
The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the...
Taylor & Francis
The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the...
Taylor & Francis
Christopher Lieu, co-director of gastrointestinal medical oncology and the associate director for clinical research at the University of Colorado Cancer Center (CO, USA) discusses the importance of biomarker testing in...
Over the past two decades, HER2-positive breast cancer has undergone a dramatic transformation in oncology. In this interview, Cristina Saura (Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology...
In this interview, Imogen Locke (The Royal Marsden NHS Foundation Trust, UK) discusses the evolving role of stereotactic ablative radiotherapy (SABR) in oligometastatic and oligoprogressive breast cancer. Locke explains...
Taylor & Francis
In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.
This podcast focuses on the real-world implications of these EMBARK findings for clinical practice.
Taylor & Francis
This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation...
In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with...
Taylor & Francis
Meet Giorgi Kobidze, your 2026 BRSA finalist.
Taylor & Francis
Meet Richa Pandey, your 2026 BRSA finalist.
Taylor & Francis
Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group
Taylor & Francis
Meet Dakshat Trivedi, your 2026 BRSA finalist.
Taylor & Francis
Meet Ethan Sanford, your 2026 BRSA finalist.
Taylor & Francis
Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye by Taylor & Francis Group
Recent guests on Taylor & Francis. Study who booked and why before you pitch.
Former WBO Middleweight Champion and author of 'Fighter.', Australian fitness brand
Chairman of the Department of Marriage and Family Sciences, Arkansas Teachers Retirement System
architect-turned-writer, O'Shaughnessy Fellow, creator of Essay Architecture, NIH's National Cancer Institute
Director of Expert Services, Alliance for Artificial Intelligence in Healthcare
PitchCentric classifies Taylor & Francis under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
